Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Haddad

Showing results (21-30 of 77) with videos related to

Pageof 8
Sort By:
Oral Oncology|August 9, 2003
Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II studyRobert Haddad, A Dimitrios Colevas, Jeffrey F Krane, et al.
Journal of Medical Economics|January 14, 2020
Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United StatesRobert Haddad, Ezra E W Cohen, Meena Venkatachalam, et al.
NPJ Precision Oncology|March 15, 2026
Integrating transcriptomic data and artificial intelligence to personalize curative treatments for head and neck cancer patientsStefano Cavalieri, Loris De Cecco, Dario Monzani, et al.
Oral Diseases|October 24, 2019
Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case seriesMuhammad Ali Shazib, Sook-Bin Woo, Hervé Sroussi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2014
Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partnersGypsyamber D'Souza, Neil D Gross, Sara I Pai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2020
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA TrialMichael C Kreissl, Lars Bastholt, Rossella Elisei, et al.
Integrated Environmental Assessment and Management|June 24, 2009
Ecological risk assessment and natural resource damage assessment: synthesis of assessment proceduresWilliam Gala, Joshua Lipton, Phil Cernera, et al.
Future Oncology (London, England)|January 10, 2024
Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study designRobert L Ferris, Hisham Mehanna, Jonathan D Schoenfeld, et al.
Integrated Environmental Assessment and Management|June 24, 2009
The Nexus between ecological risk assessment and natural resource damage assessment under CERCLA: introduction to a Society of Environmental Toxicology and ChemistryTechnical WorkshopRalph G Stahl, Ron Gouguet, David Charters, et al.
Cancer|July 28, 2009
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancerRobert Haddad, Stephen Sonis, Marshall Posner, et al.
Pageof 8

Showing results (21-30 of 77) with videos related to

Sort By:
Pageof 8
Oral Oncology|August 9, 2003
Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II studyRobert Haddad, A Dimitrios Colevas, Jeffrey F Krane, et al.
Journal of Medical Economics|January 14, 2020
Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United StatesRobert Haddad, Ezra E W Cohen, Meena Venkatachalam, et al.
NPJ Precision Oncology|March 15, 2026
Integrating transcriptomic data and artificial intelligence to personalize curative treatments for head and neck cancer patientsStefano Cavalieri, Loris De Cecco, Dario Monzani, et al.
Oral Diseases|October 24, 2019
Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case seriesMuhammad Ali Shazib, Sook-Bin Woo, Hervé Sroussi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2014
Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partnersGypsyamber D'Souza, Neil D Gross, Sara I Pai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2020
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA TrialMichael C Kreissl, Lars Bastholt, Rossella Elisei, et al.
Integrated Environmental Assessment and Management|June 24, 2009
Ecological risk assessment and natural resource damage assessment: synthesis of assessment proceduresWilliam Gala, Joshua Lipton, Phil Cernera, et al.
Future Oncology (London, England)|January 10, 2024
Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study designRobert L Ferris, Hisham Mehanna, Jonathan D Schoenfeld, et al.
Integrated Environmental Assessment and Management|June 24, 2009
The Nexus between ecological risk assessment and natural resource damage assessment under CERCLA: introduction to a Society of Environmental Toxicology and ChemistryTechnical WorkshopRalph G Stahl, Ron Gouguet, David Charters, et al.
Cancer|July 28, 2009
Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancerRobert Haddad, Stephen Sonis, Marshall Posner, et al.
Pageof 8